Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-22

Clinical Trial Update: A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001) [Phase 1]

View source ↗

Summary

Phase 1 single-dose study of MK-8892 in healthy or PAH populations to assess safety, tolerability, PK and PD; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-8892 (MK-8892)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: COMPLETED | Results posted: 2019-07-22